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ABSTRACT: A fragment of the DNA basic region (br) of the GCN4 bZIP transcription
factor has been modified to include two His residues at designed i and i+4 positions of its
N-terminus. The resulting monomeric peptide (brHis2) does not bind to its consensus
target DNA site (5′-GTCAT-3′). However, addition of Pd(en)Cl2 (en, ethylenediamine)
promotes a high-affinity interaction with exquisite selectivity for this sequence. The
peptide−DNA complex is disassembled by addition of a slight excess of a palladium
chelator, and the interaction can be reversibly switched multiple times by playing with
controlled amounts of either the metal complex or the chelator. Importantly, while the
peptide brHis2 fails to translocate across cell membranes on its own, addition of the
palladium reagent induces an efficient cell internalization of this peptide. In short, we
report (1) a designed, short peptide that displays highly selective, major groove DNA
binding, (2) a reversible, metal-dependent DNA interaction, and (3) a metal-promoted cell
internalization of this basic peptide.
■ INTRODUCTION
Protein expression depends on the concerted action of
transcription factors (TFs), which are specialized proteins
that specifically bind to regulatory DNA sequences, thereby
modulating the transcription of downstream genes.1 Over the
past few years, there has been a great interest in the
development of miniaturized models of TFs capable of
reproducing their DNA-binding properties, as they might
open interesting biomedical opportunities.2 These peptides
interact with the DNA mainly through the major groove and,
thus, might provide a compelling alternative to classic DNA
binding agents that interact by intercalation or by insertion into
the minor groove.3 However, the design and preparation of this
type of minimalistic peptides has proven extremely challeng-
ing.2,4
The most successful examples have been inspired by the
DNA binding domain of bZIP proteins such as GCN4, an
archetypal member of this family of TFs that specifically binds
to palindromic ATF/CREB (5′-ATGAC-GTCAT-3′) or AP1
(5′-ATGA(c)TCAT-3′) sites as a leucine zipper-mediated
dimer of uninterrupted α-helices.5 The DNA interaction occurs
through the N-terminal basic region (br), which folds into an α-
helix upon insertion in the major groove of the target DNA
site.6
Following the seminal work by Kim and co-workers in 1990,7
a number of groups have demonstrated that the complete
leucine zipper of the GCN4 DNA binding domain could be
replaced by artificial dimerizing elements without significantly
compromising the DNA recognition properties of the system.8
In contrast, monomeric GCN4 peptides display very low DNA
binding affinity,9 probably because the high entropic cost
associated with the folding of the peptide chain into the α-
helical conformation, required for DNA binding, is not
compensated by the enthalpic gain of a monomeric
interaction.10,11 A couple of reports have shown that
introducing lactam bridges or covalent staples can promote
DNA binding, although the affinity and selectivity of these
modified systems are rather modest.12 Better results have been
obtained by grafting key DNA binding residues from the bZIP
basic regions into stable peptide scaffolds that support the α-
helical conformation.13 In an alternative approach, our group
has demonstrated that tethering the peptides to prosthetic
minor groove binders that establish accessory stabilizing
interactions can also lead to stable DNA complexes.14
Furthermore, we have shown that such tethering can also be
achieved through a nickel-mediated coordination with
bisbenzamidine−bipyridine conjugates.15 Tethering metal-
based intercalators to peptides has also allowed cooperative
binding to DNA.16 Despite these important advances, an
efficient and selective major groove DNA interaction by simple,
minimalist peptides, featuring natural amino acids, has not been
demonstrated.
Herein we show that a designed bis-histidine grafted peptide
featuring 23 amino acids of the basic region of GCN4 binds its
consensus DNA site (5′-GTCAT-3′) with high affinity and
specificity when treated with a slight excess of [Pd(en)Cl2. The
palladium complex works as a stapling agent that favors the
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required α-helical folding and, ultimately, the insertion of the
peptide into the major groove of the target DNA (Figure 1).
Noticeably, the interaction can be reversibly switched by
controlling the relative amounts of the palladium complex and a
metal sequestering agent. Overall, we report the shortest, high-
affinity, sequence-selective DNA binding natural peptide
described so far, the first on−off, cyclically switchable peptide
DNA binder, and the use of a palladium complex to control a
selective DNA interaction.
Importantly, we have also found that the palladium clip
triggers the cellular uptake of otherwise nonpenetrating
peptides. To the best of our knowledge, this represents the
first demonstration of a metal-promoted cell internalization
process.
■ RESULTS AND DISCUSSION
Design and Synthesis. As reference for our design we
used a fragment of the GCN4 basic region comprising residues
Asp226 to Arg249.5,17 Inspection of the X-ray structure of the
GCN4/DNA complex revealed that residues Leu230 and Arg234
are oriented toward the solvent on the outer face of the α-helix,
and their substitution by His residues should not affect the
DNA contacting surface of the peptide.3a,18 Thus, we
synthesized the peptide brHis2, featuring two His residues, as
well as the natural basic region peptide (br) and the control
peptide brHis, in which only one residue is replaced by His
(Arg234 → His).
DNA Binding of the Peptide brHis2. The DNA binding
properties were studied by electrophoretic mobility assays
(EMSA) in polyacrylamide gel under nondenaturing con-
ditions, using SybrGold as the DNA stain.19 As expected,
incubation of the peptide brHis2 with the double-stranded (ds)
oligonucleotide GTCAT containing the consensus binding site
(5′-GTCAT-3′) does not induce the formation of retarded
bands (Figure 2a, lane 2), even when using a large excess of the
peptide. This is in consonance with the poor DNA affinity of
such monomeric basic regions. However, addition of 20 equiv
of Pd(en)Cl2 (en, ethylenediamine) to this mixture gives rise to
a neat, new (more retarded) band that is consistent with the
formation of the desired peptide−DNA complex GTCAT/
[(brHis2)Pd(en)]
2+ (Figure 2a, lane 3).
Importantly, the complex can be dismantled by the addition
of a small excess of an external Pd chelator (diethyldithio-
carbamate, DEDTC, Figure 2a, lane 4), a result that supports
the role of the palladium reagent in promoting the DNA
binding. Furthermore, the DNA complex can be reversibly
assembled or dismantled by controlling the relative amounts of
the Pd complex and the DEDTC (Figure 2a, lanes 4−7). To
our knowledge, reversible cyclic DNA binding of such
minimalist synthetic peptides lacks any precedent.20,21
The metal-promoted interaction is highly selective; therefore,
mutation in a single position of the target site was enough to
completely abolish the DNA binding (Figure 2b and Figure
S11). It is also important to note that neither the natural GCN4
basic region (br) nor the peptide containing a single His
mutation (brHis) gives rise to new bands in the presence of
palladium (Figure S11), which confirms the requirement of the
two coordinating histidines.
The above data are consistent with the proposed DNA
binding by a peptide monomer. Binding by a dimeric species is
unlikely, as it would require a specific arrangement of two basic
regions that are difficult to envision. Nevertheless, to fully
discard the presence of such dimeric species binding to the
DNA target, we carried out control experiments with a disulfide
dimer of the basic region peptide [br2(SS)], similar to that used
by Kim et al.17a As shown in Figure 3, the interaction of this
dipeptide with a DNA featuring either its consensus dimeric
target site (AP-1) or the monomeric half site (GTCAT) leads
to slower migrating bands than those observed for the DNA
complex with [(brHis2)Pd(en)]
2+. The retarded band observed
in lane 8 with AP1, in the presence of brHis2 and the Pd
reagent, is consistent with the insertion of two monomeric
peptides in their respective half-sites. ESI/MS analysis of the
peptide-Pd(en)2 complexes (Figure S19) and UV/vis experi-
ments with Pd(bipy)Cl2 in the presence of the target DNA
(Figure S17) also support the formation of DNA complexes
with monomeric peptides (see the Supporting Information).
DNA Binding Is Only Observed in the Presence of
Specific Metal Complexes. At this point we checked whether
other metal ions could also promote DNA binding, or if the
induction of the DNA interaction was exclusive for the
palladium reagent. As shown in Figure 4a, mixing the target
dsDNA GTCAT with brHis2 in the presence of several Ni
2+,
Figure 1. Top: Schematic structure of the supramolecular assembly
into specific DNA sites of a modified GCN4 basic region featuring two
His residues (His230 and His234, brHis2) in the presence of a metal clip.
Bottom: Sequences of the natural GCN4 basic region and the mutated
peptides brHis2 and brHis. Mutated residues are in bold.
Figure 2. DNA binding properties of brHis2. (a) Incubation with the
target ds-oligonucleotide GTCAT and switching the DNA binding by
addition of DEDTC. (b) Incubation with mutated dsDNA MUT.
Concentration of the components when present: 75 nM dsDNA, 2
μM brHis2, 20 μM Pd(en)Cl2. (a) Lane 1: dsDNA; lane 2: dsDNA
and brHis2; lane 3: previous mixture and Pd(en)Cl2; lane 4: mixture in
lane 3 after addition of 50 equiv of DEDTC; lane 5: addition of 60
equiv of Pd(en)Cl2 to the mixture in lane 4; lane 6: mixture in lane 5
after addition of 150 equiv of DEDTC; lane 7: addition of 200 equiv of
Pd(en)Cl2 to the mixture in lane 6. All the equiv are expressed relative
to brHis2. Samples were resolved on a 10% nondenaturing
polyacrylamide gel and 0.5× TBE buffer over 40 min at 25 °C and
stained with SyBrGold (5 μL in 50 mL of 1× TBE) for 10 min,
followed by fluorescence visualization. Oligonucleotide sequences
(only one strand shown, brHis2 binding site in bold): GTCAT: 5′-
CGC GTCAT AATTGAGAG CGC-3′; MUT: 5′-CGC GTGAT
AATTGAGAG CGC-3′.
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Zn2+, Cu2+, Co2+, or Fe2+ salts failed to give rise to new bands in
the EMSA (Figure 4a, lanes 4−8). It is important to highlight
the failure of NiCl2, as this metal complex had been successfully
used for promoting bivalent major−minor groove interactions
in cooperation with bisbenzamidine−bipyridine conjugates.15
However, it is not useful in the case of the more challenging
monovalent peptide−DNA interactions.
Not surprisingly, trans-[Pd(PPh3)2Cl2] also failed to induce
DNA binding, while Pd(bipy)Cl2 was roughly as effective as
Pd(en)Cl2 (Figure S12). We also proved that an analogous
complex featuring nitrate instead of chloride ligands Pd(bipy)-
(NO3)2 is also a very efficient binding trigger (Figure S12).
Therefore, it appears that square planar cis-Pd(II) complexes
present the ideal coordination properties to promote an
effective folding, and interaction to the target DNA.22 Notably,
similar PtCl2 complexes were ineffective, most probably
because of the low reactivity and kinetic stability of the
precursor salts (Figure 4b). However, electrophilic Au(III)
complexes, particularly [Au(bipy)Cl2]
+, which exhibit a square
planar geometry similar to that of Pd(II), can also promote the
DNA binding (Figure 4c). This result is quite appealing as, to
the best of our knowledge, gold complexes had never been used
in related bio-supramolecular strategies.
Spectroscopic Characterization of the Palladium-
Promoted Interaction between brHis2 and the DNA. In
order to obtain more information on the DNA binding process,
we performed fluorescence anisotropy titrations by adding
brHis2 to a solution containing 20 μM cis-[Pd(en)Cl2] and a
tetramethylrhodamine (TMR)-labeled ds-oligonucleotide con-
taining the target sequence. The addition of brHis2 led to a
progressive increase in the fluorescence anisotropy of the TMR
label. The data could be fitted to a simplified 1:1 binding model
by formally considering the complex [(brHis2)(Pd(en))]
2+ as a
single DNA binding unit, with an apparent KD ≈ 24 ± 17 nM
(Figure 5, left).
As expected for a poorly structured peptide, the circular
dichroism (CD) spectrum of brHis2 presents a relatively weak
negative signal at 222 nm, even in the presence of the
consensus DNA GTCAT (Figure 5 right). Addition of
Pd(en)Cl2 to the mixture promoted a significant increase in
the negative ellipticity at 222 nm, which is consistent with the
folding of the peptide into an α-helix (Figure 5 right, thick solid
line).23 In accordance with the results obtained by EMSA,
addition of DEDTC to the mixture resulted in a drastic
decrease in the helicity of the peptide (Figure 5 right, narrow
solid line), which correlates with the disruption of the DNA
complex. Not surprisingly, NiCl2 or Pt(en)Cl2 complexes did
not promote the peptide α-helical folding in the presence of the
target DNA (Figure S14). Interestingly, adding Pd(en)Cl2 to
brHis2, in the absence of the target DNA, gives rise only to a
relatively small increase in helicity (Figure S15). This result
raised the question of whether the palladium is coordinating the
peptide in the absence of the DNA template. UV−vis spectra
and HPLC-MS analysis of the mixture of the peptide and the
palladium complex were fully consistent with the formation of
Figure 3. Comparative EMSA experiment with monomeric brHis2 and
br2(SS). Lanes 1−4: 75 nM GTCAT; lanes 2, 3: 2 μM brHis2; lane 3:
20 μM Pd(en)Cl2; lane 4: 1.2 μM br2(SS); lanes 5−8: 75 nM AP-1;
lane 6: 1.2 μM br2(SS); lanes 7, 8: 2 μM brHis2; lane 8: 20 μM
Pd(en)Cl2. The dsDNA AP-1 features two binding sites in neighbor
sequences. We have used this ds-oligonucleotide: 5′-TGGAG ATGA
cg TCAT CTCGT-3′ (only one strand shown). Each peptide of the
disulfide br2(SS) features the sequence of peptide br (Figure 1), with
the C-terminal Arg (249) substituted by Gly-Gly-Cys.
Figure 4. DNA properties of brHis2 with different metal salts. Lane 1:
75 nM GTCAT; all other lanes: 75 nM GTCAT, 2 μM brHis2, 20 μM
metal complexes (same conditions as in Figure 2a and b). Note: The
gold dichloride complexes present a positive charge.
Figure 5. Left: Representative fluorescence anisotropy titration of a 25
nM solution of the TMR-labeled target ds-oligonucleotide TMR-
GTCAT (TMR-5′-CGCGTCATAATTGAGAGCGC-3′, only one
strand shown) in the presence of 20 μM Pd(en)Cl2 and increasing
concentrations of brHis2. The best fit to a 1:1 binding model is also
shown. Measurements were made in 20 mM Tris-HCl buffer pH 7.5
and 100 mM NaCl. Right: CD of a 5 μM solution of brHis2 (dotted
line), after the subsequent addition of 1 equiv of the target dsDNA
(dashed line), of the same solution after the addition of cis-Pd(en)Cl2
(thick solid line), and after addition of DEDTC demonstrating the
reversibility (narrow solid line). All experiments were carried out at 25
°C, in 10 mM phosphate buffer pH 7.5 and 100 mM of NaCl. The
contribution of DNA to the CD spectrum has been subtracted for
clarity. Mean residue molar ellipticity (MRE) was calculated with
respect to the 24-mer brHis2.
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the expected metal-clipped peptide (Figures S17 and S19).
Furthermore, fluorescence anisotropy experiments carried out
by adding Pd(en)Cl2 to a solution of a TMR-labeled brHis2
resulted in a progressive decrease in the anisotropy of the TMR
fluorophore at 559 nm, which agrees with the peptide acquiring
a more compact conformation (Figure S13).
The above data indicate that the Pd(II) complex does
coordinate the histidine residues, but the peptide only acquires
a high proportion of helicity after addition of the target DNA.
The palladium clip is not inducing a permanent helical
conformation as traditional helix staples,10,24 but rather it
enhances the local helical propensity, which thus facilitates the
subsequent folding in the presence of the DNA.25,10,24
Therefore, the system maintains the folding-upon-binding
behavior of the parent GCN4 transcription factor, which
might be the reason that the [(brHis2)Pd(en)]
2+ complex
shows such an excellent DNA selectivity.26
Internalization Studies: brHis2 Only Translocates in
the Presence of Pd(II). A key factor when considering
potential biological applications of this type of peptides has to
do with their ability to cross cell membranes. It is known that
basic peptides derived from transcription factors, such as the
Antennapedia, can be efficiently internalized.27 Moreover,
previous studies with covalently stapled peptides suggest that
the conformational restriction associated with the stapling
favors the cell uptake,12,28 and therefore we were curious to
know if the palladium clipping might also influence the cell
penetration ability of brHis2.
Incubation of mammalian Vero or HeLa cells with TMR-
brHis2 and 2-fold washing with phosphate-buffered saline
(PBS) revealed that despite the basic character of the peptide, it
shows a rather poor internalization.29 Gratifyingly, and also
quite surprisingly, addition of 1 equiv of Pd(en)Cl2 led to the
appearance of bright intracellular emission, which was mainly
localized in endosomes (Figures 6, S21, and S22).30
Importantly, neither the TMR-labeled basic region peptide
(TMR-br) nor the single mutated basic region (TMR-brHis)
showed appreciable cell translocations upon incubation using
similar conditions (Figure S23).
While obtaining exact information on the molecular
mechanism of the cell internalization process will require a
detailed study, we have carried out preliminary experiments
with modified peptides that shed light on the structural
requirements of the peptide for an effective metal-switched
uptake. Thus, we found that the positively charged TMR
fluorophore is not required for the metal-induced internal-
ization, so that when this fluorophore was replaced by the
anionic fluorescein (Figure S35, FITC-brHis2), the resulting
peptide replicates the palladium-induced internalization dis-
played by the parent TMR-brHis2. Similarly, the metal switch is
perfectly operative in specifically modified peptides, such as the
double mutant peptides Leu247 → Ala, Gln248 → Ala or Thr236
→ Ala, Ala238 → Thr, as well as the single mutant Ala238 → Thr.
Importantly, the cell entrance of longer peptides that include
amino acid insertions, such as one containing a Leu-Ser
fragment between Ala229 and His230, can be also regulated by
the Pd(II) reagent. Not surprisingly, the cell uptake is sensitive
to the presence of arginine residues, which is in consonance
with the well-known role of these amino acids in cell-
penetrating peptides.31 Thus, the double mutant Arg245 →
Ser; Arg249 → Ala peptide failed to translocate across the
plasmatic membrane, even in the presence of the palladium clip
(Figures 7, S33, and S34).
Although unraveling the exact structural requirements for the
cell uptake switch requires further work, these early results
indicate that the internalization requires the metal clip and the
presence of several arginine residues in the sequence, but is
highly tolerant to other changes. The underlying internalization
mechanism is also unknown, but it is likely that the clipping
effect of the palladium promotes a change in the amphiphilicity
of the system, which favors the membrane crossing. Our
peptides will require further engineering to promote endosomal
escape; however the above results represent the first examples
of a metal-triggered cell internalization of designed basic
peptides and should foster further research in this area.32
■ CONCLUSION
In summary, we have introduced a new approach for achieving
a highly selective recognition of dsDNA with a minimal (23
amino acids long), synthetic peptide that is entirely made of
natural residues. Key for the success of the approach is the
introduction of histidines in suitable i, i+4 positions in the
sequence and the addition of square-planar, Pd(II) or Au(III)
reagents. In contrast with other covalently stapled α-helical
peptides, our palladium−peptide complex is mostly unstruc-
tured in solution and acquires a predominantly helical
conformation only in the presence of the target DNA sequence.
The kinetic lability of the metal coordination facilitates the
disassembly of the supramolecular structure upon addition of
external agents that sequester the palladium.
Importantly, the DNA binding and disassembly processes
can be repeated several times, therefore providing for a fully
reversible switchable system. Also importantly, we show that
while the apo-peptide presents a very poor cellular uptake, the
Figure 6. Fluorescence micrographies of HeLa cells. Bright-field
images are superimposed to the red emission channel after incubation
with 5 μM TMR-brHis2 for 30 min at 37 °C (left) and the same
experiment in the presence of 5 μM Pd(en)Cl2 (right). The complex
was preincubated (1:1) in water for 10 min before the addition. The
cells were washed twice with PBS before being observed in a
fluorescence microscope. All incubations were made in Dulbecco’s
modified Eagle medium completed with 10% fetal bovine serum.
TMR: tetramethylrhodamine.
Figure 7. Sequences of modified peptides tested in the metal-switched
cell uptake process, highlighting the mutated residues (blue) and
whether the peptide is internalized (green dot) or does not show an
observable translocation under the same conditions (red dot).
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addition of the palladium reagent triggers an efficient
internalization. This is the first demonstration of triggering
the cell penetration of a short, basic peptide using a metal
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(2) (a) Vaźquez, M. E.; Caamaño, A. M.; Mascareñas, J. L. Chem. Soc.
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(d) Laẗtig-Tünnemann, G.; Prinz, M.; Hoffmann, D.; Behlke, J.; Palm-
Apergi, C.; Morano, I.; Herce, H. D.; Cardoso, M. C. Nat. Commun.
2011, 2, 453.
(29) (a) Milletti, F. Drug Discovery Today 2012, 17, 85. (b) Gupta,
B.; Levchenko, T. S.; Torchilin, V. P. Adv. Drug Delivery Rev. 2005, 57,
637−651. (c) Goun, E. A.; Pillow, T. H.; Jones, L. R.; Rothbard, J. B.;
Wender, P. A. ChemBioChem 2006, 7, 1497−1515. (d) Mosquera, J.;
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